Health and Healthcare
Genentech Earnings Win, But Drugs Miss (DNA)
Published:
Last Updated:
Genentech (NYSE: DNA) just announced its earnings were $0.69 EPS on $2.96 billion for the last quarter, and First Call had estimates pegged at $0.67 EPS on revenues of $2.97 Billion. The company has also guided its fiscal 2008 Earnings Per Share in a range of $3.30 to $3.47 EPS versus $3.37 estimates from First Call.
We noted that Wall Street has focused on the individual drug disappointments here from drug to drug for too long, but today’s problem is one that is hard to overlook even if you are more of a big picture sort of investor. It isn’t that it didn’t have any significant outperformance. Genentech missed on Wall Street expectations on all four of its top four drugs.
The good news is that shares of Genentech are only down about 2% at $69.15 in after-hours trading, and $65.35 is the 52-week low from December. We noted that options traders were pricing in only a move of up to about $2.50 in either direction, and the $1.49 drop is well within that range.
We’ll have to see if any downgrades come in based on all top four drugs showing disappointment win over the calls of "unbelievable valuation" and "incredible valuation" calls from Wall Street analysts. Until then, this is just an unfinished biotech earnings and post-earnings story.
Jon C. Ogg
January 14, 2008
Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
